Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer
Abstract Claudin 18.2 has emerged as a promising therapeutic target in gastric cancer based on phase 3 studies. However, clinicopathologic features associated with claudin 18.2 overexpression have not been comprehensively studied specifically for patients with resectable gastric cancer. This retrosp...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-11-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-47178-6 |
| _version_ | 1797576627183419392 |
|---|---|
| author | Hyung-Don Kim Eugene Choi Jinho Shin In-Seob Lee Chang Seok Ko Min-Hee Ryu Young Soo Park |
| author_facet | Hyung-Don Kim Eugene Choi Jinho Shin In-Seob Lee Chang Seok Ko Min-Hee Ryu Young Soo Park |
| author_sort | Hyung-Don Kim |
| collection | DOAJ |
| description | Abstract Claudin 18.2 has emerged as a promising therapeutic target in gastric cancer based on phase 3 studies. However, clinicopathologic features associated with claudin 18.2 overexpression have not been comprehensively studied specifically for patients with resectable gastric cancer. This retrospective study included 299 patients with stage I–III resectable gastric cancer who underwent curative surgical resection. Possible associations between claudin 18.2 overexpression (moderate-to-strong expression in ≥ 75% by the 43-14A clone) and clinicopathologic features and survival outcomes were analyzed. There were 90 (30.1%), 96 (32.1%), and 113 (37.8%) patients with stage I, II, and III disease, respectively. Claudin 18.2 overexpression was noted in 139 out of 299 patients (46.5%). Claudin 18.2 overexpression was associated with a younger age, a lower invasion depth limited to the mucosa/submucosa, and less frequent lymphovascular invasion. Claudin 18.2 overexpression was also associated with Borrmann type 4 among patients with advanced gastric cancer and the diffuse histological type. Claudin 18.2 overexpression was not an independent factor for survival outcomes. In conclusion, claudin 18.2 was overexpressed in almost half of resectable gastric cancer patients. Claudin 18.2 overexpression was associated with some clinicopathological characteristics, but was not an independent prognostic factor in a localized setting. |
| first_indexed | 2024-03-10T21:55:36Z |
| format | Article |
| id | doaj.art-7eddc8c5e5ef4bc8a57e943680a96f8b |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-10T21:55:36Z |
| publishDate | 2023-11-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-7eddc8c5e5ef4bc8a57e943680a96f8b2023-11-19T13:08:46ZengNature PortfolioScientific Reports2045-23222023-11-011311810.1038/s41598-023-47178-6Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancerHyung-Don Kim0Eugene Choi1Jinho Shin2In-Seob Lee3Chang Seok Ko4Min-Hee Ryu5Young Soo Park6Department of Oncology, Asan Medical Center, University of Ulsan College of MedicineDepartment of Pathology, Asan Medical Center, University of Ulsan College of MedicineDepartment of Pathology, Asan Medical Center, University of Ulsan College of MedicineDepartment of Surgery, Asan Medical Center, University of Ulsan College of MedicineDepartment of Surgery, Asan Medical Center, University of Ulsan College of MedicineDepartment of Oncology, Asan Medical Center, University of Ulsan College of MedicineDepartment of Pathology, Asan Medical Center, University of Ulsan College of MedicineAbstract Claudin 18.2 has emerged as a promising therapeutic target in gastric cancer based on phase 3 studies. However, clinicopathologic features associated with claudin 18.2 overexpression have not been comprehensively studied specifically for patients with resectable gastric cancer. This retrospective study included 299 patients with stage I–III resectable gastric cancer who underwent curative surgical resection. Possible associations between claudin 18.2 overexpression (moderate-to-strong expression in ≥ 75% by the 43-14A clone) and clinicopathologic features and survival outcomes were analyzed. There were 90 (30.1%), 96 (32.1%), and 113 (37.8%) patients with stage I, II, and III disease, respectively. Claudin 18.2 overexpression was noted in 139 out of 299 patients (46.5%). Claudin 18.2 overexpression was associated with a younger age, a lower invasion depth limited to the mucosa/submucosa, and less frequent lymphovascular invasion. Claudin 18.2 overexpression was also associated with Borrmann type 4 among patients with advanced gastric cancer and the diffuse histological type. Claudin 18.2 overexpression was not an independent factor for survival outcomes. In conclusion, claudin 18.2 was overexpressed in almost half of resectable gastric cancer patients. Claudin 18.2 overexpression was associated with some clinicopathological characteristics, but was not an independent prognostic factor in a localized setting.https://doi.org/10.1038/s41598-023-47178-6 |
| spellingShingle | Hyung-Don Kim Eugene Choi Jinho Shin In-Seob Lee Chang Seok Ko Min-Hee Ryu Young Soo Park Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer Scientific Reports |
| title | Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer |
| title_full | Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer |
| title_fullStr | Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer |
| title_full_unstemmed | Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer |
| title_short | Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer |
| title_sort | clinicopathologic features and prognostic value of claudin 18 2 overexpression in patients with resectable gastric cancer |
| url | https://doi.org/10.1038/s41598-023-47178-6 |
| work_keys_str_mv | AT hyungdonkim clinicopathologicfeaturesandprognosticvalueofclaudin182overexpressioninpatientswithresectablegastriccancer AT eugenechoi clinicopathologicfeaturesandprognosticvalueofclaudin182overexpressioninpatientswithresectablegastriccancer AT jinhoshin clinicopathologicfeaturesandprognosticvalueofclaudin182overexpressioninpatientswithresectablegastriccancer AT inseoblee clinicopathologicfeaturesandprognosticvalueofclaudin182overexpressioninpatientswithresectablegastriccancer AT changseokko clinicopathologicfeaturesandprognosticvalueofclaudin182overexpressioninpatientswithresectablegastriccancer AT minheeryu clinicopathologicfeaturesandprognosticvalueofclaudin182overexpressioninpatientswithresectablegastriccancer AT youngsoopark clinicopathologicfeaturesandprognosticvalueofclaudin182overexpressioninpatientswithresectablegastriccancer |